EnerG2 aims to improve ultracapacitors for electric cars, industry
EnerG2 Inc., an ultracapacitor startup that has kept quiet until now, is launching today with the official announcement that it has raised $8.5 million in its first round of financing. Founded in 2003, it has spent five years developing electrode materials that it claims can boost the performance of ultracapacitors, devices that are useful in electric cars and smaller electronic devices.
Unlike batteries, which store electricity chemically, ultracapacitors store energy as electrical fields and physically separate the… Continue Reading
Life-science briefing: Friday, March 14, 2008
TODAY’S HEADLINES
Cantimer takes in $2M for dehydration diagnostics (VentureWire)
Recodagen launches, takes aim at cancer (release)
Juniper Diagnostics spins out of ChemSensing (VentureWire)
Cantimer takes in $2M for dehydration diagnostics –The mystery of Menlo Park, Calif.-based Cantimer has resolved a bit. We wrote about this stealthy company back in December and reached the conclusion that the company was developing a particular type of nanosensor intended to identify water levels in human tissue.
Now VentureWire reports that Cantimer is doing… Continue Reading
Alder Bio and its yeast-produced antibodies take in $40M
Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.
Alder develops antibody-based drugs for inflammation and autoimmune disease. The company’s lead candidate, ALD518, is currently in clinical trials as a treatment for rheumatoid arthritis and cancer, although neither Alder’s Web site nor its statement disclose when the drug began human tests.
Alder’s work… Continue Reading
Life sciences briefing: Wednesday, Sept. 26, 2007
Featured companies: Ablynx, Cardiosolutions, Carigent Thereapeutics, Elusys, Genome Corp., GlobeImmune, Novazone, Targanta Therapeutics, Waterfront Media
UPDATED at 5:45am on 9/27/07
GlobeImmune raises $41M for immune-system therapies — GlobeImmune, a Louisville, Colo., biotech focused on new forms of immunotherapy to treat viral infections and cancer, raised $41.2 million in a third funding round. Investors included Wexford Capital, Celgene, the Mellon Family Investment Company, the Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, HealthCare Ventures,… Continue Reading
Life sciences briefing: Wednesday, Sept. 5, 2007
Featured companies: Atritech, Avalon Partners, Ensemble Discovery, Hyperion Therapeutics, LifeBond, ReShape Medical, SafeStitch, Trophos, UltraShape
Hyperion Therapeutics raises $40M against GI and kidney disease — Hyperion Therapeutics, a South San Francisco, Calif., specialty pharmaceutical company, raised $40 million in a second funding round. Investors included Sofinnova Ventures, Highland Capital Partners, New Enterprise Associates and WRF Capital.
Hyperion, which buys the rights to test and market drug candidates from other companies, said the proceeds will allow it to complete… Continue Reading
Farecast, the airfare prediction site, raises $12.1M more
Farecast.com, the young Seattle start-up that now owns the niche of predicting airfares, and which continues to roll out new features (like letting you guarantee low fares), has raised $12.1 million more.
The round was led by Sutter Hill Ventures, and includes PAR Capital Management, Pinnacle Ventures, and Farecast board member and former Expedia CEO, Erik Blachford. Existing investors, Greylock Partners, Madrona Venture Group, and WRF Capital also participated — it has raised a total of… Continue Reading